Mark Rubinstein

Dr. Mark Rubinstein


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LZLei Zhou
Lei Zhou
MVMaria Velegraki
Maria Velegraki
YWYi Wang
Yi Wang
JMJay Mandula
Jay Mandula
YCYuzhou Chang
Yuzhou Chang
ZLZihai Li
Zihai Li
Intratumoral Tregs are key mediators of cancer immunotherapy resistance, including anti–programmed cell death (ligand) 1 [anti–PD-(L)1] immune checkpoint blockade (ICB). The mechanisms driving Treg infiltration into the tumor microenvironment (TME) and the consequence on CD8 + T cell exhaustion remain elusive. Here, we report that heat shock protein gp96 (also known as GRP94) was indispensable for Treg tumor infiltration, primarily through the roles of gp96 in chaperoning integrins. Among various gp96-dependent integrins, we found that only LFA-1 (αL integrin), and not αV, CD103 (αE), or β7 integrin, was required for Treg tumor homing. Loss of Treg infiltration into the TME by genetic deletion of gp96/LFA-1 potently induced rejection of tumors in multiple ICB-resistant murine cancer models in a CD8 + T cell–dependent manner, without loss of self-tolerance. Moreover, gp96 deletion impeded Treg activation primarily by suppressing IL-2/STAT5 signaling, which also contributed to tumor regression. By competing for intratumoral IL-2, Tregs prevented the activation of CD8 + tumor-infiltrating lymphocytes, drove thymocyte selection-associated high mobility group box protein (TOX) induction, and induced bona fide CD8 + T cell exhaustion. By contrast, Treg ablation led to striking CD8 + T cell activation without TOX induction, demonstrating clear uncoupling of the 2 processes. Our study reveals that the gp96/LFA-1 axis plays a fundamental role in Treg biology and suggests that Treg-specific gp96/LFA-1 targeting represents a valuable strategy for cancer immunotherapy without inflicting autoinflammatory conditions.

18 February 2025 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
ZLZihai Li
Zihai Li
JWJohn Wrangle
John Wrangle
KHKai He
Kai He
JSJonathan Sprent
Jonathan Sprent
MRMark Rubinstein
Mark Rubinstein

4 September 2023 in Immuno
Verified
Journal Article
Open access
PDF file
BABindu Adhikari
Bindu Adhikari
EOEugene M. Oltz
Eugene M. Oltz
JBJoseph S. Bednash
Joseph S. Bednash
JHJeffrey C. Horowitz
Jeffrey C. Horowitz
Joshua Oluoch AmimoJoshua Oluoch Amimo
Joshua Oluoch Amimo
AVAnastasia N. Vlasova
Anastasia N. Vlasova
The impact of pre-existing common cold coronavirus (CCCoV) antibodies (Abs) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and pathogenesis remains poorly defined. We evaluated these associations in a cohort of hospitalized patients with COVID-19 and respiratory failure of varying severity. Patients with respiratory failure from other causes (non-COVID-19) were evaluated as controls. We demonstrated a positive correlation between levels of CCCoV and SARS-CoV-2 Abs using CCCoV and SARS-CoV-2 N and S protein peptide-specific ELISA. Consistent with the above, moderately increased levels of CCCoV-specific Abs in non-COVID-19 vs. COVID-19 patients suggest potential protective effects. Further, higher SARS-CoV-2 N protein-specific and CCCoV Ab levels were observed among surviving vs. non-surviving COVID-19 positive patients. However, the highest SARS-CoV-2 N and S protein-specific IgG and IgA Ab levels were noted in the patients with the most severe clinical disease. Finally, advanced age, cancer and immunosuppression were associated with significantly higher mortality and reduced SARS-CoV-2 and CCCoV Ab levels. Thus, our data highlight that sufficient SARS-CoV-2 N protein-specific Ab responses improve clinical outcomes in severely ill COVID-19 patients. We also confirmed that pre-existing CCCoV-specific Abs do not inhibit the SARS-CoV-2 Ab response and may further reduce the prevalence and/or severity of COVID-19.

2 May 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ZLZihai Li
Zihai Li
JAJoseph H. Azar
Joseph H. Azar
MRMark Rubinstein
Mark Rubinstein
Summary: Dose-limiting toxicities are thought to temper the efficacy of single-agent 4-1BB agonists. To overcome this hurdle, in this issue of Cancer Discovery, Muik and colleagues report preclinical and clinical studies describing a first-in-class bispecific fusion protein targeting 4-1BB and PD-L1. See related article by Muik et al., p. 1248 (9).

18 March 2022 in medRxiv
Verified
Preprint
Open access
PDF file
JAJoseph Azar
Joseph Azar
JEJohn P. Evans
John P. Evans
MSMadison Sikorski
Madison Sikorski
KCKarthik Chakravarthy
Karthik Chakravarthy
SMSelah McKenney
Selah McKenney
MRMark Rubinstein
Mark Rubinstein
The impact of SARS-CoV2 vaccination in cancer patients remains incompletely understood given the heterogeneity of cancer and cancer therapies. We assessed vaccine-induced antibody response to the SARS-CoV2 Omicron (B.1.1.529) variant in 57 patients with B cell malignancies with and without active B cell-targeted therapy. Ancestral- and Omicron-reactive antibody levels were determined by ELISA and neutralization assays. In over one third of vaccinated patients at the pre-booster timepoint, there were no ELISA-detectable antibodies against either the ancestral strain or Omicron variant. The lack of vaccine-induced antibodies was predominantly in patients receiving active therapy such as anti-CD20 monoclonal antibody (mAb) or Bruton’s tyrosine kinase inhibitors (BTKi). While booster immunization was able to induce detectable antibodies in a small fraction of seronegative patients, the benefit was disproportionately evident in patients not on active therapy. Importantly, in patients with post-booster ELISA-detectable antibodies, there was a positive correlation of antibody levels against the ancestral strain and Omicron variant. Booster immunization increased overall antibody levels, including neutralizing antibody titers against the ancestral strain and Omicron variant; however, predominantly in patients without active therapy. Furthermore, ancestral strain neutralizing antibody titers were about 5-fold higher in comparison with those to Omicron, suggesting that even with booster administration, there may be reduced protection against the Omicron variant. Interestingly, in almost all patients regardless of active therapy, including those unable to generate detectable antibodies against SARS-CoV2 spike, we observed comparable levels of EBV, influenza, and common cold coronavirus reactive antibodies demonstrating that B cell-targeting therapies primarily impair de novo but not pre-existing antibody levels. These findings suggest that patients with B cell malignancies on active therapy may be at disproportionately higher risk to new versus endemic viral infection and suggest utility for vaccination prior to B cell-targeted therapy.

19 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
FBFahmin Basher
Fahmin Basher
TSTyler Aaron Smith
Tyler Aaron Smith
MRMark Rubinstein
Mark Rubinstein
Jennifer WuJennifer Wu
Jennifer Wu
Background/Objectives: Antigen-specific adoptive CD8+ T-cell therapy has demonstrated promising clinical activity in selected cancers; however, its broader efficacy against solid tumors remains limited by the immunosuppressive tumor microenvironment (TME), which compromises the persistence and function of transferred T-cells. A clinically relevant component of the human solid-tumor TME is soluble MHC class I chain-related molecules A and B (sMICA and sMICB, collectively termed sMIC), which are tumor-derived soluble NKG2D ligands that are not naturally expressed in mice. sMIC promotes tumor immune evasion through multiple mechanisms, but whether therapeutic clearance of sMIC can enhance the efficacy of adoptive T-cell therapy remains unclear. Methods: B16F10 melanoma cells engineered to express soluble MICB (B16F10-sMICB) were implanted subcutaneously into syngeneic B6/MICB mice. Once tumors became palpable, mice were randomized to four treatment groups: (1) no treatment; (2) adoptive transfer of gp100-specific Pmel CD8+T cells; (3) the sMIC-targeting monoclonal antibody B10G5; or (4) B10G5 combined with Pmel adoptive cell transfer. Pmel CD8+T cells were administered once intravenously, and B10G5 was administered intraperitoneally twice weekly at approximately 3 mg/kg. Tumor growth and body weight were monitored twice weekly. To determine the contribution of natural killer (NK) cells to the therapeutic effect of the combination treatment, NK cells were depleted using the anti-NK1.1 antibody PK136. The impact of NK cells on CD8+T cell function during B10G5/sMIC stimulation was further evaluated ex vivo. Results: Therapeutic targeting of sMIC with B10G5 significantly enhanced the antitumor efficacy of adoptively transferred Pmel CD8+T cells and was associated with increased donor T-cell persistence, tumor infiltration, and antigen-specific effector function. NK cell depletion markedly diminished the antitumor efficacy of the B10G5/Pmel combination and reduced the abundance, activation, and effector function of donor CD8+ T-cells. Consistent with these in vivo findings, ex vivo depletion of NK cells impaired IFN-γ production by NKG2D+CD8+ T-cells during B10G5/sMIC stimulation, supporting a functional role for NK cells in sustaining CD8+T cell responses. Conclusions: These findings provide evidence that therapeutic targeting of tumor-derived sMIC can enhance the efficacy of antigen-specific adoptive CD8+T cell therapy by promoting the persistence and function of transferred T-cells. Importantly, our results identify NK cells as critical contributors to the enhanced therapeutic response, revealing functional cooperation between NK cells and adoptively transferred CD8+T cells during sMIC-targeted therapy. Together, these findings provide preclinical proof-of-concept for combining sMIC-targeting antibodies with adoptive T-cell therapy to improve antitumor immunity against sMIC+ solid tumors.